American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 33-40, January 2009

Meta-analysis of N-Acetylcysteine to Prevent Acute Renal Failure After Major Surgery

  • Kwok M. Ho, MBBS, MPH, FRCP, FANZCA, FJFICM

      Affiliations

    • Corresponding Author InformationAddress correspondence to Kwok M. Ho, MBBS, MPH, FRCP, FANZCA, FJFICM, ICU, Royal Perth Hospital, Perth, WA 6000, Australia
  • ,
  • David J.R. Morgan, MBBS, FACEM, FJFICM

Intensive Care Unit, Royal Perth Hospital, Perth, WA, Australia

Received 12 February 2008; accepted 7 May 2008. published online 24 July 2008.

Background

Acute renal failure after major surgery is associated with significant mortality and morbidity that theoretically may be attenuated by N-acetylcysteine.

Design

Meta-analysis of relevant studies sourced from the Cochrane Controlled Trial Register (2007 issue 4), EMBASE, and MEDLINE databases (1966 to February 1, 2008) without language restriction.

Setting & Population

Adult patients undergoing major surgery without the use of radiocontrast.

Selection Criteria for Studies

Randomized controlled studies comparing N-acetylcysteine with a placebo perioperatively.

Data Analysis

Categorical variables are reported as odds ratio (OR) with 95% confidence interval (CI), and continuous variables are reported as weighted-mean-difference (WMD) with 95% CI.

Outcome Measures

Effects of N-acetylcysteine on mortality and acute renal failure requiring dialysis were the main outcomes of interest. Additional outcome measures included an incremental increase in serum creatinine concentration greater than 25% above baseline, surgical reexploration for bleeding, amount of allogeneic blood transfusion, and length of intensive care unit stay.

Results

10 studies involving a total of 1,193 adult patients undergoing major surgery were considered. N-Acetylcysteine use was not associated with a decrease in mortality (OR, 1.05; 95% CI, 0.58 to 1.92), acute renal failure requiring dialysis (OR, 1.04; 95% CI, 0.45 to 2.37), incremental increase in serum creatinine concentration greater than 25% above baseline (OR, 0.84; 95% CI, 0.64 to 1.11), or length of intensive care unit stay (WMD in days, 0.46; 95% CI, −0.43 to 1.36). N-Acetylcysteine did not appear to increase the risk of surgical reexploration for bleeding (OR, 1.16; 95% CI, 0.57 to 2.38) or amount of allogeneic blood transfusion required (WMD in units, 0.31; 95% CI, −0.21 to 0.84).

Limitations

Most studied patients had cardiac surgery and normal renal function preoperatively.

Conclusions

There is no current evidence that N-acetylcysteine used perioperatively can alter mortality or renal outcomes when radiocontrast is not used.

Index Words: Length of stay, mortality, renal dysfunction, renal protection

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2008.05.019 on July 25, 2008.

PII: S0272-6386(08)00958-X

doi:10.1053/j.ajkd.2008.05.019

American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 33-40, January 2009